News
LADX
2.140
0.00%
0.000
Weekly Report: what happened at LADX last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at LADX last week (0408-0412)?
Weekly Report · 04/15 12:21
Weekly Report: what happened at LADX last week (0401-0405)?
Weekly Report · 04/08 12:27
Weekly Report: what happened at LADX last week (0325-0329)?
Weekly Report · 04/01 12:23
Weekly Report: what happened at LADX last week (0318-0322)?
Weekly Report · 03/25 12:27
Weekly Report: what happened at LADX last week (0311-0315)?
Weekly Report · 03/18 12:25
Weekly Report: what happened at LADX last week (0304-0308)?
Weekly Report · 03/11 12:19
Weekly Report: what happened at LADX last week (0226-0301)?
Weekly Report · 03/04 12:24
Weekly Report: what happened at LADX last week (0219-0223)?
Weekly Report · 02/26 12:45
Weekly Report: what happened at LADX last week (0212-0216)?
Weekly Report · 02/19 12:47
Weekly Report: what happened at LADX last week (0205-0209)?
Weekly Report · 02/12 12:31
Weekly Report: what happened at LADX last week (0129-0202)?
Weekly Report · 02/05 12:44
Weekly Report: what happened at LADX last week (0122-0126)?
Weekly Report · 01/29 12:26
Weekly Report: what happened at LADX last week (0115-0119)?
Weekly Report · 01/22 12:33
Weekly Report: what happened at LADX last week (0108-0112)?
Weekly Report · 01/15 12:26
Xoma to pay $1M to LadRx as rare disease therapy undergoes FDA review
Healthcare Xoma to pay $1M to LadRx as rare disease therapy undergoes FDA review Jan. 12, 2024. Xoma Corporation announced it would pay £1M in milestone payments to Ladrx Corporation for rare disease treatment arimoclomol. The drug targets patients with Niemann-Pick disease type C.
Seeking Alpha · 01/12 12:44
Xoma to Make $1M Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol
Xoma will make a $1 million milestone payment to LadRx following the U.S. Food and Drug Administration's acceptance of Zevra Therapeutics' new drug application for arimoclomol. The drug is a therapy for Niemann-Pick disease type C, a genetic disorder.
Dow Jones · 01/11 21:20
Weekly Report: what happened at LADX last week (0101-0105)?
Weekly Report · 01/08 12:33
Weekly Report: what happened at LADX last week (1225-1229)?
Weekly Report · 01/01 12:24
Weekly Report: what happened at LADX last week (1218-1222)?
Weekly Report · 12/25/2023 12:42
More
Webull provides a variety of real-time LADX stock news. You can receive the latest news about LadRx through multiple platforms. This information may help you make smarter investment decisions.
About LADX
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.